Literature DB >> 11906489

Role of nitric oxide in mediating vasodilator responses to opioid peptides in the rat.

Hunter C Champion1, Trinity J Bivalacqua, James E Zadina, Abba J Kastin, Albert L Hyman, Philip J Kadowitz.   

Abstract

1. Endomorphins 1 and 2, endogenous ligands for the mu-opioid receptor, and nociceptin (orphanin FQ; OFQ), an endogenous ligand for the ORL1 receptor, have vasodilator activity in the vascular bed of the hindquarters of the rat. In the present study, the role of nitric oxide (NO), vasodilator prostaglandins and the opening of KATP channels in mediating vasodilator responses to these novel agonists was investigated in the rat. 2. Under constant-flow conditions, injections of endomorphins 1 and 2, PL017 ([N-MePhe3,D-Pro4]-morphiceptin), nociceptin and Tyr-D-Ala-Gly-MePhe-Gly(ol)-enkephalin (DAMGO) produced dose-dependent decreases in hindquarters perfusion pressure. Vasodilator responses to endomorphin 1 and 2, acetylcholine and adrenomedullin, were attenuated by the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) at a time when vasodilator responses to nociceptin, adrenomedullin and the NO donor diethylamine/NO were not altered. 3. Vasodilator responses to endomorphins 1 and 2, nociceptin, PL017 and DAMGO were not altered after administration of sodium meclofenamate at a time when vasodilator responses to arachidonic acid were reduced significantly or after administration of U-37883A at a time when vasodilator responses to levcromakalim were reduced significantly. 4. The results of these studies indicate that vasodilator responses to endomorphins 1 and 2, PL017 and DAMGO are mediated, in large part, by the release of NO, whereas vasodilator responses to nociceptin are mediated by an L-NAME-insensitive mechanism. Moreover, these results demonstrate that the vasodilator responses to these peptides are not due to the release of vasodilator prostaglandins or the opening of KATP channels in the hindquarters vascular bed of the rat.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906489     DOI: 10.1046/j.1440-1681.2002.03634.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  Functional pharmacological characterization of SER100 in cardiovascular health and disease.

Authors:  Inmaculada C Villar; Kristen J Bubb; Amie J Moyes; Eva Steiness; Trygve Gulbrandsen; Finn Olav Levy; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

2.  Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats.

Authors:  L Jolly; J E March; P A Kemp; T Bennett; S M Gardiner
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

3.  ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.

Authors:  U Simonsen; B E Laursen; J S Petersen
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

4.  Effect of Endomorphins on HUVECs Treated by ox-LDL and Its Related Mechanisms.

Authors:  Juan Zhao; Qi Zhang; Jing Liu; Liming Tian; Wenhui Huang; Jinxing Quan; Jinyang Wang; Yanjia Xu; Yunfang Wang; Ruilan Niu
Journal:  J Diabetes Res       Date:  2016-08-04       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.